Hara Capital LLC Acquires Shares of 3,255 Bio-Rad Laboratories, Inc. $BIO

Hara Capital LLC bought a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO) in the 3rd quarter, Holdings Channel reports. The firm bought 3,255 shares of the medical research company’s stock, valued at approximately $913,000.

Several other hedge funds also recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its stake in Bio-Rad Laboratories by 25.2% in the first quarter. Royal Bank of Canada now owns 30,310 shares of the medical research company’s stock worth $7,382,000 after purchasing an additional 6,100 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Bio-Rad Laboratories by 45.6% in the first quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company’s stock worth $25,575,000 after buying an additional 32,874 shares during the period. Empowered Funds LLC lifted its stake in shares of Bio-Rad Laboratories by 14.8% during the 1st quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company’s stock worth $377,000 after acquiring an additional 199 shares during the last quarter. Jane Street Group LLC boosted its holdings in Bio-Rad Laboratories by 95.3% during the 1st quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company’s stock valued at $9,105,000 after acquiring an additional 18,239 shares during the period. Finally, Voya Investment Management LLC grew its position in Bio-Rad Laboratories by 7.1% in the 1st quarter. Voya Investment Management LLC now owns 2,461 shares of the medical research company’s stock valued at $599,000 after acquiring an additional 164 shares during the last quarter. 65.24% of the stock is currently owned by institutional investors.

Insider Transactions at Bio-Rad Laboratories

In other news, EVP James Barry sold 700 shares of Bio-Rad Laboratories stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $306.18, for a total value of $214,326.00. Following the transaction, the executive vice president directly owned 510 shares in the company, valued at approximately $156,151.80. This trade represents a 57.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Trading Down 2.1%

NYSE BIO opened at $304.94 on Friday. Bio-Rad Laboratories, Inc. has a one year low of $211.43 and a one year high of $373.69. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.94 and a current ratio of 5.44. The company has a market capitalization of $8.23 billion, a price-to-earnings ratio of -12.54 and a beta of 1.18. The company’s 50-day simple moving average is $312.71 and its two-hundred day simple moving average is $296.08.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Wednesday, October 29th. The medical research company reported $2.26 earnings per share for the quarter, missing the consensus estimate of $2.30 by ($0.04). The business had revenue of $653.00 million during the quarter, compared to analysts’ expectations of $651.30 million. Bio-Rad Laboratories had a positive return on equity of 4.19% and a negative net margin of 26.43%.Bio-Rad Laboratories’s revenue for the quarter was up .5% on a year-over-year basis. During the same period in the previous year, the company posted $2.01 EPS. Equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Analyst Ratings Changes

BIO has been the subject of several research analyst reports. Citigroup lifted their target price on Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Wall Street Zen upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Wells Fargo & Company upped their target price on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Monday, December 29th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Bio-Rad Laboratories currently has an average rating of “Hold” and a consensus price target of $358.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.